JOHNSON & JOHNSON - FORM 8-K - EX-99.2O - EXHIBIT

Attached files

file	filename
8-K - 8-K - JOHNSON & JOHNSON	a3q20128kcover.htm
EX-99.15 - EXHIBIT - JOHNSON & JOHNSON	a3q20128kexhibit9915.htm

Exhibit 99.2O



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	THIRD QUARTER

	2012						2011						Percent
					Percent						Percent		Increase
	Amount				to Sales		Amount				to Sales		(Decrease)
Sales to customers	$	17,052			100.0		$	16,005			100.0		6.5
Cost of products sold	5,597				32.8		5,072				31.7		10.4
Selling, marketing and administrative expenses	5,228				30.6		5,240				32.7		(0.2	)
Research and development expense	1,923				11.3		1,773				11.1		8.5
In-process research and development	679				4.0		—				—
Interest (income) expense, net	120				0.7		117				0.7
Other (income) expense, net	(90		)		(0.5	)	(308		)		(1.9	)
Earnings before provision for taxes on income	3,595				21.1		4,111				25.7		(12.6	)
Provision for taxes on income	966				5.7		909				5.7		6.3
Net earnings	2,629				15.4		3,202				20.0		(17.9	)
Add: Net loss attributable to noncontrolling interest	339				2.0		—				—
Net earnings attributable to Johnson & Johnson	$	2,968			17.4		$	3,202			20.0		(7.3	)

Net earnings per share attributable to Johnson & Johnson (Diluted)	$	1.05					$	1.15					(8.7	)

Average shares outstanding (Diluted)	2,818.1						2,778.2

Effective tax rate	26.9			%			22.1			%

Adjusted earnings before provision for taxes and net earnings
attributable to Johnson & Johnson ^{(1) (A)}
Earnings before provision for taxes on income	$	4,525			26.5		$	4,427			27.7		2.2
Net earnings attributable to Johnson & Johnson	$	3,521			20.6		$	3,443			21.5		2.3
Net earnings per share attributable to Johnson & Johnson (Diluted)	$	1.25					$	1.24					0.8
Effective tax rate	22.2			%			22.2			%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings attributable to Johnson & Johnson," "adjusted net earnings per share attributable to Johnson & Johnson (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings attributable to Johnson & Johnson, adjusted net earnings per share attributable to Johnson & Johnson (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	NINE MONTHS

	2012				2011						Percent
				Percent					Percent		Increase
	Amount			to Sales	Amount				to Sales		(Decrease)
Sales to customers	$	49,666		100.0	$	48,775			100.0		1.8
Cost of products sold	15,655			31.5	15,022				30.8		4.2
Selling, marketing and administrative expenses	15,208			30.6	15,511				31.8		(2.0	)
Research and development expense	5,334			10.7	5,393				11.0		(1.1	)
In-process research and development	1,108			2.2	—				—
Interest (income) expense, net	379			0.8	332				0.7
Other (income) expense, net	1,307			2.7	(115		)		(0.2	)
Restructuring expense	—			—	589				1.2
Earnings before provision for taxes on income	10,675			21.5	12,043				24.7		(11.4	)
Provision for taxes on income	2,728			5.5	2,589				5.3		5.4
Net earnings	7,947			16.0	9,454				19.4		(15.9	)
Add: Net loss attributable to noncontrolling interest	339			0.7	—				—
Net earnings attributable to Johnson & Johnson	$	8,286		16.7	$	9,454			19.4		(12.4	)

Net earnings per share attributable to Johnson & Johnson (Diluted)	$	2.96			$	3.40					(12.9	)

Average shares outstanding (Diluted)	2,805.0				2,777.6

Effective tax rate	25.6		%		21.5			%

Adjusted earnings before provision for taxes and net earnings
attributable to Johnson & Johnson^{(1) (A)}
Earnings before provision for taxes on income	$	14,099		28.4	$	13,696			28.1		2.9
Net earnings attributable to Johnson & Johnson	$	10,969		22.1	$	10,738			22.0		2.2
Net earnings per share attributable to Johnson & Johnson (Diluted)	$	3.91			$	3.87					1.0
Effective tax rate	22.2		%		21.6			%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings attributable to Johnson & Johnson," "adjusted net earnings per share attributable to Johnson & Johnson (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings attributable to Johnson & Johnson, net earnings per share attributable to Johnson & Johnson (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings attributable to Johnson & Johnson, adjusted net earnings per share attributable to Johnson & Johnson (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	THIRD QUARTER
				Percent Change
	2012		2011	Total			Operations		Currency
Sales to customers by
segment of business

Consumer
U.S.	$	1,214	1,219	(0.4	)	%	(0.4	)	—
International	2,367		2,521	(6.1	)		1.8		(7.9	)
	3,581		3,740	(4.3	)		1.0		(5.3	)

Pharmaceutical
U.S.	3,288		2,869	14.6			14.6		—
International	3,114		3,113	0.0			8.2		(8.2	)
	6,402		5,982	7.0			11.3		(4.3	)

Med Devices & Diagnostics
U.S.	3,289		2,780	18.3			18.3		—
International	3,780		3,503	7.9			14.4		(6.5	)
	7,069		6,283	12.5			16.1		(3.6	)

U.S.	7,791		6,868	13.4			13.4		—
International	9,261		9,137	1.4			8.9		(7.5	)
Worldwide	$	17,052	16,005	6.5		%	10.8		(4.3	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	NINE MONTHS
				Percent Change
	2012		2011	Total			Operations		Currency
Sales to customers by
segment of business

Consumer
U.S.	$	3,843	3,903	(1.5	)	%	(1.5	)	—
International	6,952		7,312	(4.9	)		1.4		(6.3	)
	10,795		11,215	(3.7	)		0.4		(4.1	)

Pharmaceutical
U.S.	9,408		9,499	(1.0	)		(1.0	)	—
International	9,418		8,775	7.3			14.1		(6.8	)
	18,826		18,274	3.0			6.3		(3.3	)

Med Devices & Diagnostics
U.S.	9,119		8,521	7.0			7.0		—
International	10,926		10,765	1.5			6.2		(4.7	)
	20,045		19,286	3.9			6.5		(2.6	)

U.S.	22,370		21,923	2.0			2.0		—
International	27,296		26,852	1.7			7.5		(5.8	)
Worldwide	$	49,666	48,775	1.8		%	5.0		(3.2	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	THIRD QUARTER
				Percent Change
	2012		2011	Total			Operations	Currency
Sales to customers by
geographic area

U.S.	$	7,791	6,868	13.4		%	13.4	—

Europe	3,983		4,124	(3.4	)		7.1	(10.5	)
Western Hemisphere excluding U.S.	1,824		1,751	4.2			12.8	(8.6	)
Asia-Pacific, Africa	3,454		3,262	5.9			9.0	(3.1	)
International	9,261		9,137	1.4			8.9	(7.5	)

Worldwide	$	17,052	16,005	6.5		%	10.8	(4.3	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	NINE MONTHS
				Percent Change
	2012		2011	Total			Operations	Currency
Sales to customers by
geographic area

U.S.	$	22,370	21,923	2.0		%	2.0	—

Europe	12,342		12,850	(4.0	)		4.2	(8.2	)
Western Hemisphere excluding U.S.	5,266		4,730	11.3			19.1	(7.8	)
Asia-Pacific, Africa	9,688		9,272	4.5			6.1	(1.6	)
International	27,296		26,852	1.7			7.5	(5.8	)

Worldwide	$	49,666	48,775	1.8		%	5.0	(3.2	)



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Third Quarter					% Incr. /
(Dollars in Millions Except Per Share Data)	2012				2011	(Decr.)

Earnings before provision for taxes on income - as reported	$	3,595			4,111	(12.6	)	%

Intangible asset write-downs/adjustments	(30		)		—

Net litigation	—				—

Synthes integration/transaction costs and currency related	165			⁽¹⁾	316

In-process research and development	679				—

Restructuring - Cordis	—				—

DePuy ASR™ Hip related costs	116				—

Earnings before provision for taxes on income - as adjusted	$	4,525			4,427	2.2		%

Net Earnings attributable to Johnson & Johnson - as reported	$	2,968			3,202	(7.3	)	%

Intangible asset write-downs	(16		)		—

Net litigation	—				—

Synthes integration/transaction costs and currency related	135				241

In-process research and development	340			⁽²⁾	—

Restructuring - Cordis	—				—

DePuy ASR™ Hip related costs	94				—

Net Earnings attributable to Johnson & Johnson - as adjusted	$	3,521			3,443	2.3		%

Diluted Net Earnings per share attributable to Johnson & Johnson - as reported	$	1.05			1.15	(8.7	)	%

Intangible asset write-downs	(0.01		)		—

Net litigation	—				—

Synthes integration/transaction costs and currency related	0.05				0.09

In-process research and development	0.13				—

Restructuring - Cordis	—				—

DePuy ASR™ Hip related costs	0.03				—

Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted	$	1.25			1.24	0.8		%

⁽¹⁾ Represents inventory step-up recorded in cost of products sold

⁽²⁾ In-process research and development of $679M offset by $339M reported as net loss attributable to noncontrolling interest

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Nine Months YTD				% Incr. /
(Dollars in Millions Except Per Share Data)	2012		2011		(Decr.)

Earnings before provision for taxes on income - as reported	$	10,675	$	12,043	(11.4	)	%

Intangible asset write-downs/adjustments	909		—

Net litigation	669		576

Synthes integration/transaction costs and currency related	622		214

In-process research and development	1,108		—

Restructuring - Cordis	—		676

DePuy ASR™ Hip related costs	116		187

Earnings before provision for taxes on income - as adjusted	$	14,099	13,696		2.9		%

Net Earnings attributable to Johnson & Johnson - as reported	$	8,286	9,454		(12.4	)	%

Intangible asset write-downs	701		—

Net litigation	611		444

Synthes integration/transaction costs and currency related	593		139

In-process research and development	684		—

Restructuring - Cordis	—		549

DePuy ASR™ Hip related costs	94		152

Net Earnings attributable to Johnson & Johnson - as adjusted	$	10,969	10,738		2.2		%

Diluted Net Earnings per share attributable to Johnson & Johnson - as reported	$	2.96	3.40		(12.9	)	%

Intangible asset write-downs	0.25		—

Net litigation	0.22		0.16

Synthes integration/transaction costs and currency related	0.21		0.05

In-process research and development	0.24		—

Restructuring - Cordis	—		0.20

DePuy ASR™ Hip related costs	0.03		0.06

Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted	$	3.91	3.87		1.0		%

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		THIRD QUARTER
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	104	105	(1.0	)%	(1.0	)%	—	%
Intl		460	508	(9.4	)	(2.1	)	(7.3	)
WW		564	613	(8.0	)	(1.9	)	(6.1	)

ORAL CARE
US		162	162	0.0		0.0		—
Intl		251	260	(3.5	)	4.7		(8.2	)
WW		413	422	(2.1	)	3.0		(5.1	)

OTC/NUTRITIONALS
US		351	332	5.7		5.7		—
Intl		709	722	(1.8	)	6.0		(7.8	)
WW		1,060	1,054	0.6		5.9		(5.3	)

SKIN CARE
US		390	376	3.7		3.7		—
Intl		514	567	(9.3	)	(2.2	)	(7.1	)
WW		904	943	(4.1	)	0.2		(4.3	)

WOMEN'S HEALTH
US		81	104	(22.1	)	(22.1	)	—
Intl		326	354	(7.9	)	2.3		(10.2	)
WW		407	458	(11.1	)	(3.2	)	(7.9	)

WOUND CARE/OTHER
US		126	140	(10.0	)	(10.0	)	—
Intl		107	110	(2.7	)	4.5		(7.2	)
WW		233	250	(6.8	)	(3.6	)	(3.2	)

TOTAL CONSUMER
US		1,214	1,219	(0.4	)	(0.4	)	—
Intl		2,367	2,521	(6.1	)	1.8		(7.9	)
WW	$	3,581	3,740	(4.3	)%	1.0	%	(5.3	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		THIRD QUARTER
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	1,600	1,390	15.1	%	15.1	%	—	%
Intl		484	377	28.4		37.1		(8.7	)
WW		2,084	1,767	17.9		19.8		(1.9	)
REMICADE
US		940	876	7.3		7.3		—
US Exports⁽³⁾		379	343	10.5		10.5		—
Intl		272	189	43.9		53.2		(9.3	)
WW		1,591	1,408	13.0		14.3		(1.3	)
SIMPONI
US		93	59	57.6		57.6		—
Intl		92	70	31.4		39.7		(8.3	)
WW		185	129	43.4		47.9		(4.5	)
STELARA
US		188	112	67.9		67.9		—
Intl		99	77	28.6		39.5		(10.9	)
WW		287	189	51.9		56.4		(4.5	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		21	41	(48.8	)	(46.6	)	(2.2	)
WW		21	41	(48.8	)	(46.6	)	(2.2	)

INFECTIOUS DISEASES
US		259	216	19.9		19.9		—
Intl		536	498	7.6		18.0		(10.4	)
WW		795	714	11.3		18.6		(7.3	)
INTELENCE
US		45	42	7.1		7.1		—
Intl		49	41	19.5		32.1		(12.6	)
WW		94	83	13.3		19.5		(6.2	)
LEVAQUIN/FLOXIN
US		10	14	(28.6	)	(28.6	)	—
Intl		10	11	(9.1	)	(4.8	)	(4.3	)
WW		20	25	(20.0	)	(18.1	)	(1.9	)
PREZISTA
US		181	132	37.1		37.1		—
Intl		183	184	(0.5	)	9.9		(10.4	)
WW		364	316	15.2		21.3		(6.1	)
OTHER INFECTIOUS DISEASES
US		23	28	(17.9	)	(17.9	)	—
Intl		294	262	12.2		22.6		(10.4	)
WW		317	290	9.3		18.7		(9.4	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		THIRD QUARTER
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	678	634	6.9	%	6.9	%	—	%
Intl		990	1,050	(5.7	)	1.2		(6.9	)
WW		1,668	1,684	(1.0	)	3.3		(4.3	)
CONCERTA/METHYLPHENIDATE
US		150	179	(16.2	)	(16.2	)	—
Intl		104	104	0.0		6.8		(6.8	)
WW		254	283	(10.2	)	(7.7	)	(2.5	)
INVEGA
US		78	74	5.4		5.4		—
Intl		62	52	19.2		26.9		(7.7	)
WW		140	126	11.1		14.3		(3.2	)
INVEGA SUSTENNA/XEPLION
US		130	85	52.9		52.9		—
Intl		82	16	*		*		(8.7	)
WW		212	101	*		*		(3.4	)
RISPERDAL CONSTA
US		113	111	1.8		1.8		—
Intl		238	279	(14.7	)	(7.2	)	(7.5	)
WW		351	390	(10.0	)	(4.6	)	(5.4	)
OTHER NEUROSCIENCE
US		207	185	11.9		11.9		—
Intl		504	599	(15.9	)	(10.3	)	(5.6	)
WW		711	784	(9.3	)	(5.0	)	(4.3	)

ONCOLOGY
US		145	79	83.5		83.5		—
Intl		483	415	16.4		27.3		(10.9	)
WW		628	494	27.1		36.2		(9.1	)
DOXIL/CAELYX
US		9	10	(10.0	)	(10.0	)	—
Intl		7	76	(90.8	)	(89.6	)	(1.2	)
WW		16	86	(81.4	)	(80.4	)	(1.0	)
VELCADE
US		—	—	—		—		—
Intl		327	295	10.8		20.7		(9.9	)
WW		327	295	10.8		20.7		(9.9	)
ZYTIGA
US		136	69	97.1		97.1		—
Intl		129	26	*		*		(10.7	)
WW		265	95	*		*		(5.2	)
OTHER ONCOLOGY
US		—	—	—		—		—
Intl		20	18	11.1		18.8		(7.7	)
WW		20	18	11.1		18.8		(7.7	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		THIRD QUARTER
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

TOTAL OTHER
US	$	606	550	10.2	%	10.2	%	—	%
Intl		621	773	(19.7	)	(12.8	)	(6.9	)
WW		1,227	1,323	(7.3	)	(3.3	)	(4.0	)
ACIPHEX/PARIET
US		80	94	(14.9	)	(14.9	)	—
Intl		115	141	(18.4	)	(9.2	)	(9.2	)
WW		195	235	(17.0	)	(11.5	)	(5.5	)
PROCRIT/EPREX
US		198	176	12.5		12.5		—
Intl		161	207	(22.2	)	(14.6	)	(7.6	)
WW		359	383	(6.3	)	(2.2	)	(4.1	)
OTHER
US		328	280	17.1		17.1		—
Intl		345	425	(18.8	)	(13.1	)	(5.7	)
WW		673	705	(4.5	)	(1.1	)	(3.4	)

TOTAL PHARMACEUTICAL
US		3,288	2,869	14.6		14.6		—
Intl		3,114	3,113	0.0		8.2		(8.2	)
WW	$	6,402	5,982	7.0	%	11.3	%	(4.3	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		THIRD QUARTER
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES AND DIAGNOSTICS ^{(2) (4)}

CARDIOVASCULAR CARE
US	$	195	198	(1.5	)%	(1.5	)%	—	%
Intl		298	328	(9.1	)	(3.3	)	(5.8	)
WW		493	526	(6.3	)	(2.7	)	(3.6	)

DIABETES CARE
US		328	338	(3.0	)	(3.0	)	—
Intl		301	326	(7.7	)	0.8		(8.5	)
WW		629	664	(5.3	)	(1.1	)	(4.2	)

DIAGNOSTICS
US		256	265	(3.4	)	(3.4	)	—
Intl		257	274	(6.2	)	(0.5	)	(5.7	)
WW		513	539	(4.8	)	(1.9	)	(2.9	)

INFECTION PREVENTION/OTHER
US		98	90	8.9		8.9		—
Intl		134	130	3.1		9.0		(5.9	)
WW		232	220	5.5		9.0		(3.5	)

ORTHOPAEDICS
US		1,242	737	68.5		68.5		—
Intl		1,048	647	62.0		68.7		(6.7	)
WW		2,290	1,384	65.5		68.6		(3.1	)

SPECIALTY SURGERY
US		308	292	5.5		5.5		—
Intl		289	284	1.8		9.1		(7.3	)
WW		597	576	3.6		7.2		(3.6	)

SURGICAL CARE ⁽⁵⁾
US		602	609	(1.1	)	(1.1	)	—
Intl		949	1,013	(6.3	)	0.9		(7.2	)
WW		1,551	1,622	(4.4	)	0.1		(4.5	)

VISION CARE
US		260	251	3.6		3.6		—
Intl		504	501	0.6		4.8		(4.2	)
WW		764	752	1.6		4.4		(2.8	)

TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		3,289	2,780	18.3		18.3		—
Intl		3,780	3,503	7.9		14.4		(6.5	)
WW	$	7,069	6,283	12.5	%	16.1	%	(3.6	)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		NINE MONTHS
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	309	315	(1.9	)%	(1.9	)%	—	%
Intl		1,373	1,457	(5.8	)	0.3		(6.1	)
WW		1,682	1,772	(5.1	)	(0.1	)	(5.0	)

ORAL CARE
US		476	483	(1.4	)	(1.4	)	—
Intl		732	729	0.4		7.1		(6.7	)
WW		1,208	1,212	(0.3	)	3.7		(4.0	)

OTC/NUTRITIONALS
US		1,068	1,059	0.8		0.8		—
Intl		2,128	2,207	(3.6	)	2.5		(6.1	)
WW		3,196	3,266	(2.1	)	2.0		(4.1	)

SKIN CARE
US		1,314	1,251	5.0		5.0		—
Intl		1,410	1,520	(7.2	)	(1.4	)	(5.8	)
WW		2,724	2,771	(1.7	)	1.5		(3.2	)

WOMEN'S HEALTH
US		254	350	(27.4	)	(27.4	)	—
Intl		964	1,044	(7.7	)	0.2		(7.9	)
WW		1,218	1,394	(12.6	)	(6.7	)	(5.9	)

WOUND CARE/OTHER
US		422	445	(5.2	)	(5.2	)	—
Intl		345	355	(2.8	)	3.0		(5.8	)
WW		767	800	(4.1	)	(1.5	)	(2.6	)

TOTAL CONSUMER
US		3,843	3,903	(1.5	)	(1.5	)	—
Intl		6,952	7,312	(4.9	)	1.4		(6.3	)
WW	$	10,795	11,215	(3.7	)%	0.4	%	(4.1	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		NINE MONTHS
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	4,524	4,350	4.0	%	4.0	%	—	%
Intl		1,374	652	*		*		(5.7	)
WW		5,898	5,002	17.9		19.2		(1.3	)
REMICADE
US		2,712	2,500	8.5		8.5		—
US Exports⁽³⁾		1,123	1,360	(17.4	)	(17.4	)	—
Intl		800	204	*		*		(5.7	)
WW		4,635	4,064	14.1		15.1		(1.0	)
SIMPONI
US		220	173	27.2		27.2		—
Intl		206	118	74.6		83.0		(8.4	)
WW		426	291	46.4		49.8		(3.4	)
STELARA
US		469	317	47.9		47.9		—
Intl		287	214	34.1		43.3		(9.2	)
WW		756	531	42.4		46.1		(3.7	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		81	116	(30.2	)	(27.2	)	(3.0	)
WW		81	116	(30.2	)	(27.2	)	(3.0	)

INFECTIOUS DISEASES
US		738	1,191	(38.0	)	(38.0	)	—
Intl		1,600	1,282	24.8		34.1		(9.3	)
WW		2,338	2,473	(5.5	)	(0.7	)	(4.8	)
INTELENCE
US		130	118	10.2		10.2		—
Intl		135	113	19.5		29.2		(9.7	)
WW		265	231	14.7		19.4		(4.7	)
LEVAQUIN/FLOXIN
US		35	585	(94.0	)	(94.0	)	—
Intl		30	33	(9.1	)	(4.2	)	(4.9	)
WW		65	618	(89.5	)	(89.2	)	(0.3	)
PREZISTA
US		507	386	31.3		31.3		—
Intl		554	509	8.8		17.7		(8.9	)
WW		1,061	895	18.5		23.5		(5.0	)
OTHER INFECTIOUS DISEASES
US		66	102	(35.3	)	(35.3	)	—
Intl		881	627	40.5		50.4		(9.9	)
WW		947	729	29.9		38.4		(8.5	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		NINE MONTHS
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	2,010	2,006	0.2	%	0.2	%	—	%
Intl		3,019	3,203	(5.7	)	(0.4	)	(5.3	)
WW		5,029	5,209	(3.5	)	(0.2	)	(3.3	)
CONCERTA/METHYLPHENIDATE
US		493	667	(26.1	)	(26.1	)	—
Intl		337	327	3.1		9.1		(6.0	)
WW		830	994	(16.5	)	(14.5	)	(2.0	)
INVEGA
US		223	219	1.8		1.8		—
Intl		180	155	16.1		21.5		(5.4	)
WW		403	374	7.8		10.0		(2.2	)
INVEGA SUSTENNA/XEPLION
US		350	220	59.1		59.1		—
Intl		218	23	*		*		(7.1	)
WW		568	243	*		*		(2.7	)
RISPERDAL CONSTA
US		336	335	0.3		0.3		—
Intl		731	863	(15.3	)	(9.4	)	(5.9	)
WW		1,067	1,198	(10.9	)	(6.7	)	(4.2	)
OTHER NEUROSCIENCE
US		608	565	7.6		7.6		—
Intl		1,553	1,835	(15.4	)	(11.3	)	(4.1	)
WW		2,161	2,400	(10.0	)	(6.9	)	(3.1	)

ONCOLOGY
US		371	236	57.2		57.2		—
Intl		1,439	1,249	15.2		23.6		(8.4	)
WW		1,810	1,485	21.9		29.0		(7.1	)
DOXIL/CAELYX
US		22	130	(83.1	)	(83.1	)	—
Intl		31	233	(86.7	)	(85.4	)	(1.3	)
WW		53	363	(85.4	)	(84.6	)	(0.8	)
VELCADE
US		—	—	—		—		—
Intl		998	922	8.2		15.7		(7.5	)
WW		998	922	8.2		15.7		(7.5	)
ZYTIGA
US		349	106	*		*		—
Intl		348	43	*		*		(8.5	)
WW		697	149	*		*		(4.2	)
OTHER ONCOLOGY
US		—	—	—		—		—
Intl		62	51	21.6		28.1		(6.5	)
WW		62	51	21.6		28.1		(6.5	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		NINE MONTHS
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

TOTAL OTHER
US	$	1,765	1,716	2.9	%	2.9	%	—	%
Intl		1,986	2,389	(16.9	)	(11.6	)	(5.3	)
WW		3,751	4,105	(8.6	)	(5.5	)	(3.1	)
ACIPHEX/PARIET
US		280	304	(7.9	)	(7.9	)	—
Intl		369	417	(11.5	)	(4.1	)	(7.4	)
WW		649	721	(10.0	)	(5.7	)	(4.3	)
PROCRIT/EPREX
US		634	623	1.8		1.8		—
Intl		502	632	(20.6	)	(14.5	)	(6.1	)
WW		1,136	1,255	(9.5	)	(6.4	)	(3.1	)
OTHER
US		851	789	7.9		7.9		—
Intl		1,115	1,340	(16.8	)	(12.5	)	(4.3	)
WW		1,966	2,129	(7.7	)	(5.0	)	(2.7	)

TOTAL PHARMACEUTICAL
US		9,408	9,499	(1.0	)	(1.0	)	—
Intl		9,418	8,775	7.3		14.1		(6.8	)
WW	$	18,826	18,274	3.0	%	6.3	%	(3.3	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		NINE MONTHS
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES AND DIAGNOSTICS ^{(2) (4)}

CARDIOVASCULAR CARE
US	$	566	650	(12.9	)%	(12.9	)%	—	%
Intl		913	1,098	(16.8	)	(13.0	)	(3.8	)
WW		1,479	1,748	(15.4	)	(13.0	)	(2.4	)
DIABETES CARE
US		1,017	982	3.6		3.6		—
Intl		955	1,000	(4.5	)	1.9		(6.4	)
WW		1,972	1,982	(0.5	)	2.8		(3.3	)
DIAGNOSTICS
US		767	811	(5.4	)	(5.4	)	—
Intl		772	799	(3.4	)	0.9		(4.3	)
WW		1,539	1,610	(4.4	)	(2.3	)	(2.1	)
INFECTION PREVENTION/OTHER
US		313	283	10.6		10.6		—
Intl		393	385	2.1		6.2		(4.1	)
WW		706	668	5.7		8.1		(2.4	)
ORTHOPAEDICS
US		2,898	2,318	25.0		25.0		—
Intl		2,513	2,038	23.3		28.3		(5.0	)
WW		5,411	4,356	24.2		26.5		(2.3	)
SPECIALTY SURGERY
US		971	899	8.0		8.0		—
Intl		900	874	3.0		8.7		(5.7	)
WW		1,871	1,773	5.5		8.3		(2.8	)
SURGICAL CARE ⁽⁵⁾
US		1,797	1,826	(1.6	)	(1.6	)	—
Intl		3,019	3,117	(3.1	)	2.2		(5.3	)
WW		4,816	4,943	(2.6	)	0.8		(3.4	)
VISION CARE
US		790	752	5.1		5.1		—
Intl		1,461	1,454	0.5		2.9		(2.4	)
WW		2,251	2,206	2.0		3.6		(1.6	)

TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		9,119	8,521	7.0		7.0		—
Intl		10,926	10,765	1.5		6.2		(4.7	)
WW	$	20,045	19,286	3.9	%	6.5	%	(2.6	)%
*Percentage greater than 100%
⁽¹⁾Operational growth excludes the effect of currency
⁽²⁾ Select areas (unaudited)
⁽³⁾Reported as U.S. sales
⁽⁴⁾Prior year amounts have been reclassified to conform to current year product disclosure
⁽⁵⁾ Previously referred to as General Surgery

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports

JOHNSON & JOHNSON - FORM 8-K - EX-99.2O - EXHIBIT - October 16, 2012

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports